MacroGenics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

MacroGenics, Inc. (Nasdaq: MGNX) announced its participation in significant investor conferences in March 2023. The company's President & CEO, Scott Koenig, will join the TD Cowen’s 43rd Annual Health Care Conference in Boston on March 7, 2023, for a corporate panel discussion. Additionally, he will participate in a fireside chat at the Barclays Global Healthcare Conference in Miami on March 14, 2023. Management will also engage in one-on-one meetings during both events. Webcasts of the presentations will be available on the company's Investor Relations website, with an archived replay for 30 days.

ROCKVILLE, MD, March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March 2023:

• TD Cowen’s 43^rd Annual Health Care Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in the GI/GU Oncology Corporate Panel Discussion on Tuesday, March 7, 2023, at 12:50 pm ET.  MacroGenics’ management will also participate in one-on-one meetings; and
• Barclays Global Healthcare Conference (Miami). Scott Koenig, M.D., Ph.D. will participate in a fireside chat on Tuesday, March 14, 2023, at 9:30 am ET. MacroGenics’ management will also participate in one-on-one meetings.

A webcast of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.  The Company will maintain an archived replay of these webcasts on its website for 30 days.

About MacroGenics, Inc.

MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

FAQ

What events is MacroGenics participating in March 2023?

MacroGenics is participating in the TD Cowen’s 43rd Annual Health Care Conference on March 7 and the Barclays Global Healthcare Conference on March 14, 2023.

Who is representing MacroGenics at the conferences?

Scott Koenig, M.D., Ph.D., President & CEO, will represent MacroGenics at both conferences.

Where can I watch the MacroGenics conference presentations?

The presentations can be accessed via the 'Events & Presentations' section on MacroGenics' Investor Relations website.

How long will the webcasts of the MacroGenics presentations be available?

The archived replay of the webcasts will be available for 30 days on MacroGenics' website.

What is the focus area of MacroGenics?

MacroGenics focuses on developing and commercializing innovative antibody-based therapeutics for cancer treatment.